|Awarded On||November 19, 2014|
|Title||Novel Separase Inhibitors to Treat Refractory Breast Cancer|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Debananda Pati|
Currently there is no good therapy for two subtypes of human breast cancers (BC) which have aggressive disease phenotype, often resulting in high mortality. They include the triple negative BC (TNBC), and the endocrine resistant Luminal B subtypes. According to the American Cancer Society, in 2013, there were 232,340 new cases of invasive BC (15,000 in the State of Texas) and 39,620 BC-related deaths in the US. Since 15-20% of the total BC comprises of TNBC and 20% of Luminal B subtypes, it can be estimated that in 2013, ~100,000 women had these deadly forms of BC which contribute to majority of the BC-related deaths.
Our goal is to develop a new class of drugs targeted for these hard-to-tre...